SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Makers Laboratories - Quaterly Results

07 Nov 2023 Evaluate
The sales figure stood at Rs. 149.23 millions for the September 2023 quarter. The mentioned figure indicates a growth of about 30.77% as compared to Rs. 114.12 millions during the year-ago period.The Net Loss for the quarter ended September 2023 is Rs. -9.89 millions as compared to Net Loss of Rs. -7.13 millions of corresponding quarter ended September 2022Operating profit Margin for the quarter ended September 2023 slipped to -0.28% as compared to 1.00% of corresponding quarter ended September 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 149.23 114.12 30.77 264.67 210.79 25.56 425.47 523.76 -18.77
Other Income 6.92 6.88 0.58 8.82 8.22 7.30 11.37 8.48 34.08
PBIDT -0.28 1.00 -128.00 -16.23 -12.88 26.01 -29.97 38.97 -176.91
Interest 4.05 3.27 23.85 7.53 6.96 8.19 13.81 16.75 -17.55
PBDT -4.33 -2.27 90.75 -23.76 -19.84 19.76 -43.78 22.22 -297.03
Depreciation 6.80 6.01 13.14 13.49 10.80 24.91 23.99 19.07 25.80
PBT -11.13 -8.28 34.42 -37.25 -30.64 21.57 -67.77 3.15 -2251.43
TAX -1.24 -1.15 7.83 -2.77 -0.78 255.13 -4.15 1.41 -394.33
Deferred Tax -1.24 -1.15 7.83 -2.77 -0.78 255.13 -4.30 1.08 -498.15
PAT -9.89 -7.13 38.71 -34.48 -29.86 15.47 -63.62 1.74 -3756.32
Equity 59.00 59.00 0.00 59.00 59.00 0.00 59.00 49.17 19.99
PBIDTM(%) -0.19 0.88 -121.41 -6.13 -6.11 0.36 -7.04 7.44 -194.67

Makers Laboratories Share Price

155.80 -4.35 (-2.72%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×